A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
A Prospective Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
Sponsor: The University of Hong Kong
This PHASE3 trial investigates Deep Vein Thrombosis and Pulmonary Embolism and is currently ongoing. The University of Hong Kong leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The University of Hong Kong
For direct contact, visit the study record on ClinicalTrials.gov .